Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Drugmaker Eli Lilly and Co. spent $2.2 million in the fourth quarter of 2009 lobbying the federal government on intellectual
property rights, anti-counterfeiting measures and health care reform, among other issues.
The Indianapolis drugmaker also lobbied on patient safety issues, ambassadorial nominations for the United Nations, research,
and pricing and access issues for several countries, according to a lobbying report filed with the House of Representatives.
Lilly's $2.2 million total spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional
debate over health care reform peaked during the last quarter of 2009. In contrast, several health insurers increased their
lobbying spending by 20 percent or more in last year's final quarter.
Besides Congress, Lilly lobbied the U.S. Trade Representative, the Patent & Trademark Office, the National Security Council,
the Food and Drug Administration, and the departments of Commerce, State, Agriculture, and Health and Human Services.
Among those lobbying on Lilly's behalf in the October-December period were J. Savonne Caughey, former senior adviser
to the undersecretary for the Department of Agriculture.
Please enable JavaScript to view this content.